June 2026 in “The Journal of Sexual Medicine” This study determined that men taking finasteride 1 mg/day exhibited significantly reduced sperm production and morphology compared to controls, although there were no notable changes in hormonal, sexual, or psychological function.
November 2025 in “Zenodo (CERN European Organization for Nuclear Research)” In this study, Saw Palmetto at a physiological dose partially inhibited 5-α-reductase and improved hormonal balance, inflammation, and mitochondrial function, with synergy observed when combined with Lycopene, L-Arginine, and Astaxanthin, enhancing male prostatic and endocrine health without endocrine side effects.
November 2025 in “Zenodo (CERN European Organization for Nuclear Research)” This study reported that Saw Palmetto, at a physiological dose, partially inhibits 5-alpha-reductase and, when combined with Lycopene, L-Arginine, and Astaxanthin, demonstrates a synergistic effect in restoring hormonal balance, reducing inflammation, and improving hair density, urinary flow, and oxidative biomarkers in related male health conditions.
June 2026 in “HAL (Le Centre pour la Communication Scientifique Directe)” This article presents the SH-1 molecule as a novel AR antagonist for androgenetic alopecia treatment, highlighting its tissue-specific action and potential for commercialization, but provides no new clinical results.
June 2026 in “Zenodo (CERN European Organization for Nuclear Research)” This source describes SH‑1 as a next-generation androgen receptor antagonist designed for localized treatment of androgenetic alopecia, aiming to reverse follicular miniaturization while maintaining endocrine balance. Unlike traditional therapies, SH‑1 offers tissue-specific action, avoiding systemic effects.